DOCSLIB.ORG

A A20, 156–157, 386, 423 AB12, 326 ABCA1 Transporter, 395 Abelson

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A A20, 156–157, 386, 423 AB12, 326 ABCA1 Transporter, 395 Abelson Index A AGI-5198, 218 A20, 156–157, 386, 423 AhR-KO mice, 417 AB12, 326 AIM2, 85 ABCA1 transporter, 395 Aiolos (IKZF3), 179 Abelson murine leukemia virus (A-MuLV), AKAP450, 204 165, 193 Akt, 424, 445 ABL, 472 Alarmin, 119–120, 430 ABO blood type, 98 Aldehyde dehydrogenase 1 (ALDH1), 187 Abscopal effect, 463 ALK1, 243 ACE-KO mice, 410 Allo-antibodies, 100 Acetylcholine (Ach), 127 Allogenic, 306 Acetyl-CoA (coenzyme A), 211 Allograft, 306 Activated protein C (rhAPC), 454 α-ketoglutarate (α-KG), 215 Adalimumab, 356 α-linoleic acid (ALA), 458 ADAM10, 109, 263, 335 α 1, 3 galactosyltransferase, 98 ADAM12, 264, 416 α 1, 3 N-acetylgalactosaminyl (GalNAc) ADAM15, 264 transferase, 98 ADAM17, 152, 264, 275 α7 nAchR, 397 ADAMTS1, 264, 265 α smooth muscle actin (α-SMA), 235 ADAMTS2, 265 Alpha2 plasmin inhibitor (α2PI), 59 ADAMTS9, 265 Alzheimer’s disease, 110 ADAMTS13, 265 AMD3100, 360, 405 Adenine nucleotide translocase (ANT), 206 Amelanotic melanoma cells, 454 Adenylate cyclase, 397 American Society of Clinical Oncology Adherens junction (AJ), 42, 249, 473 (ASCO), 437 Adhesion, 42 Ammonia, 363 Adipose tissue, 332, 383–384 AMP-activated protein kinase (AMPK), 214, A Disintegrin and Metalloprotease (ADAM), 216, 373 253 Amyloid fibrils, 110 Adjuvant, 122 Amyloid precursor protein (APP), 110 Advanced bladder cancer, 189 Anakinra (IL-1ra), 154 Advanced glycation end product (AGE), 109 Anaphylatoxins, 30 AE3-208, 429, 458 Anchorage-independent three-dimensional Aggregation, 59 growth, 194 Aggresome, 393 Androgen receptor (AR), 224 © Springer Japan 2016 489 Y. Maru, Inflammation and Metastasis, DOI 10.1007/978-4-431-56024-1 490 Index Aneuploidy, 204 ATP11C, 29 Angiopoietin 1 (Ang1), 53, 245 Atrial natriuretic peptide (ANP), 408, 410 Angiopoietin 2 (Ang2), 408 Autoantibody, 67, 146 Angiotensin-converting enzyme (ACE), 410 Autograft, 306 Angiotensin II (ATII), 383, 408, 410 Autoimmune disorders, 146 Angiotropism, 269–270, 339–340, 404, 466 Autoinflammatory diseases (AID), 145 ANGPTL4, 444, 445 Autophagosome, 367 Annexin A1, 12 Autophagy, 210, 393 AntagomiR, 474 Antibladder cancer immunotherapy, 314 Antibody-dependent cell-mediated B cytotoxicity (ADCC), 223 B7-H1, 316 Anti-CD4 antibody (GK1.5), 406 B16, 358 Anti-CD40 antibody, 442 B16 melanoma cell, 333 Antigen-presenting cells (APC), 24 B16F10 melanoma, 405 Anti-Gr-1 (Ly6G) RB6-8C5, 306 B7-1, 442 Anti-RANKL antibody, 457 B27, 288 Anti-S100A8 antibody, 358 Bacillus Calmette-Guerin (BCG), 469 Antithrombin III (ATIII), 59 Bactericidal/permeability-increasing protein Anti-TNFα antibody, 358 (BPI), 89 Anti-VEGF therapy, 184 BAD, 206 Anti-VEGFR1 antibody, 358 Bafilomycin A1, 217 2-APB, 336 BAPTA, 72 AP endonuclease (APE1), 202 Basigin, 268, 370 Aplasia Ras homolog member I (ARHI), 367 BAX, 206 Apocynin, 247 BCL-2, 165, 179, 206 ApoE, 120 BCL-2 homology (BH) domain, 206 Apoptosis, 30 Bcl-XL, 280 Apoptosis-associated speck-like protein, 148 BCR-ABL, 165 Apurinic/apyrimidinic-1 (AP-1), 54, 385 Beclin-1 (ATG6), 217 Apyrase, 78 Beige mice, 171 Aquaporin (AQP), 53–54 Belt desmosome, 42 Arachidonic acid (AA), 12, 411, 458 Benzothiazole dye thioflavin T, 110 Arginase 1, 323, 465 Bernard, Claude, 379 Aripiprazole, 114 β-aminopropionitrile (BAPN), 364 ARNT, 219 β-arrestin, 244 ARP-1, 475 β defensins, 68 Arp2/3, 267 β-galactosidase (SA- β-GAL) activity, 209 Aryl hydrocarbon receptor (AhR), 417 β-hydroxylase (DBH), 277 ASCT2, 215 β tryptase, 97 Aspergillus niger, 456 Bevacizumab, 47 Aspergillus oryzae (PAO), 141 Biglycan, 132–136 Asthma model, 406 Biliverdin, 119 Ataxia-telangiectasia, 182 Biomarkers, 167 ATF3, 280, 415, 423 Blast crisis (BC), 177 ATF3-KO mice, 423 Blau syndrome, 157 ATG5, 444 Blood brain barrier (BBB), 70 ATG12, 217 BLT1, 459 ATI, 410 BML-258, 470 ATII type A1 receptor (AT1A), 383, 409 BMP, 363 ATM, 182 Bortezomib, 460 Atopic dermatitis, 71 Brachyrury, 288 ATP, 118, 150, 220 Brachyury, 107 Index 491 Bradykinin, 51 Castration-resistant prostate cancer cells BRAF, 197 (CRPC), 224, 225 BRAF V600E, 439 Catabasis, 12 BRAFGV600E, 442 Cathelicidin, 12 Brain-derived neurotropic factor (BDNF), 333 Cathepsin-G, 97 BRCA1, 180 Caveolae, 43 BrdU-positive, 321 Caveolin-1, 47 Breast cancer, 183 Cbl, 205 Breast cancer metastasis suppressor Cbl-b, 423, 457 1 (BRMS1), 475 Cbl-b-KO mice, 457 Brodalumab, 73 CC10, 60 Bronchoalveolar lavage (BAL), 391 CC10-KO mice, 406 Btk, 34 CCL2, 64, 358, 362, 395, 417 Burst-forming unit-erythroid (BFU-E), 170 CCL2-CCR2 signaling, 468 Busulfan, 178 CCL2-KO mice, 427 Butyrate, 218 CCL3, 359, 463 BYK191023, 270 CCL3 (MIP-1α), 111 CCL4 (MIP-1 β), 111 CCL5, 285, 367 C CCL11, 330 C1q, 30, 31 CCL21, 418 C1q/TNF-related protein-3 (CTRP-3), 138 CCR7, 25 C3b, 33 CCSP-KO mice, 392 C3H/HeJ mouse, 88 CDC42, 49 C-26, 306 CD1d, 368 C57BL/10ScCr (null allele), 88 CD4+ T cells, 170 Ca2+,8 CD11b, 423 Cabozantinib, 471 CD14, 87 Cachexia, 157 CD18, 9 Caenorhabditis elegans,8 CD18 (¼β2 integrin), 415 CA15-3, 185 CD18-KO, 419 Caki-2, 334 CD19, 324 Calcein, 429 CD24, 187 Calcineurin, 155, 424 CD31, 43 Calcineurin inhibitors (CI), 155 CD31 (¼ PECAM), 277 Calcipressin 1, 407 CD36, 109, 247, 467 Calcium-sensing receptor (CaR), 278, 282 CD40L, 57 Campylobacter jejuni,69 CD44, 117, 187, 242 Canakinumab, 157 CD44s, 266 Cancer, 165 CD45.1, 306, 321 Cancer cachexia, 312–313 CD45.2 congenic chimera mice, 306, 321 Cancer of unknown primary (CUP), 350 CD62L, 380 Cancer stem cells (CSC), 272 CD85j, 422 Capsicum, 97 CD90/Thy1, 289 Carbohydrate mimicry, 69 CD91, 119 Carbon monoxide (CO), 119, 237–238 CD105 (endoglin), 279 Carboxymethyl lysine (CML), 109 CD117 (c-Kit), 282 Carcinoma-associated fibroblasts (CAFs), 272 CD120a, 152 Carcinomatosa, 437 CD132, 101 Cardiofaciocutaneous syndrome, 197 CD133, 285 Casein kinase 1α (CK1α), 388 CD133+ CD44+ cells, 332 Caspase-1, 158 CD137 (4-1BB), 327 Caspase-11, 91 CD138, 240 492 Index CD146, 43, 242 66 cl4 breast cancer cells, 333 CD147, 268, 370, 415, 422, 468 CLI-095, 466 CD152, 442 Clodronate, 77 CD163, 118 Clonal divergence, 286–287 CD166, 274 Cloudman S91 melanoma, 352 CD169, 274 Club cells, 392–393 CD274, 316 Club cell secretory protein (CCSP), 392 CD279, 442 CML-initiating cells, 177 CDC50A, 29 Coagulation, 335 CEA, 185, 354 Coagulation cascade, 55–57 C/EBPβ, 390 Coco, 363 Cecal ligation, 460 Codominant, 88 Cediranib, 337 Colchicine, 95 Celastramycin A, 94 Collagen, 47 Cell adhesion molecule (CAM), 9 Collagen-induced arthritis, 472 Cellular inhibitor of apoptosis proteins (cIAP-1 Colony-forming unit-fibroblast (CFU-F), 169 and -2), 386 Colony-forming unit-granulocyte/macrophage Celsus, 4 (CFU-GM), 170 Central nervous system (CNS), 332 Colorectal cancer (CRC), 404 Centrosome, 204 Common myeloid precursor (CMP), 169, 170, Ceramide, 393 382 Cereblon, 179 Communicating junction, 43 c-fos, 385 Complement, 33 CF transmembrane conductance regulator Complement-dependent cytotoxicity (CDC) (CFTR), 392 test, 101 CFU-granulocyte/erythroid/macrophage/ Complex junction (c-Jun), 43, 152 megakaryocyte (GEMM), 170 Complex I, 219, 220 cGMP-dependent protein kinase (PKG), 47 Complex III, 219 Chediak-Higashi syndrome (CHS), 156 Complexus adherens, 43 Chemerin, 12 Concomitant tumor resistance, 352 Chemerin 15, 12 Confidence interval (CI), 440 Chemokine-like receptor 1 (CMKLR1), 12 Congenic, 306 ChemR23, 12 Connexin, 43 Chimeric antigen receptor (CAR), 324 Connexin43, 429 CHIP, 205 Contact guidance, 315, 330 Chk2, 201 CO-releasing molecule (CORM), 237 Chloroacetate esterase staining, 419 Corpora amylacea, 420 Chondroitin sulfate, 116 Costello syndrome, 197 Chorioallantoic membrane (CAM) Counter-receptor system, 381 angiogenesis assay, 248 COX2, 147, 444 Chromosomal instability (CIN), 204 CPA-7, 470 Chromothripsis, 204, 286 CR1 (CD35), 34 Chronic granulomatous disease (CGD), 0, 36 CR3 (CD11b-CD18), 33 Chronic hepatitis, 404 CR4 (CD11c-CD18), 33 Chronic lymphocytic leukemia (CLL), 324 CRACM1, 336 Chronic myeloid leukemia, 165 C-reactive protein (CRP), 14, 475 Chymase, 71 Crohn’s disease, 156 Circulating tumor cells (CTC), 165, 186, 331, Cryopyrin, 148 351 Cryopyrin-associated periodic syndrome Class switch recombination (CSR), 169, 178 (CAPS), 157 Clathrin, 47 CSF-1, 362 Claudin, 43 CUB domain-containing protein-1 (CDCP1), Clenbuterol, 277 339 Index 493 Curcumin, 96 Dextran sodium sulfate (DSS), 391 CX3CL1, 320 Diatomic molecules, 236–238 CX3CR1, 319 Dicer, 474 CXC subfamily chemokines, 391 Dihydroxyeicosatrienoic acid (DHET), 411 CXCL1, 70, 334, 362, 415, 468 9,10-Dimethyl-1,2-benzanthracene (DMBA), CXCL1 (GROα), 391 310 CXCL1-S100A8 loop, 468 Dinaciclib, 289 CXCL2, 78, 468 2,4-Dinitrofluorobenzene, 329 CXCL2 (GROβ), 391 Diphenyleneiodonium, 247 CXCL2 (MIP-2), 111 Diptericin, 93 CXCL4, 246 DIRAS3, 367 CXCL8, 391 Disintegrin, 253 CXCL12, 365, 462 Disseminated intravascular coagulopathy CXCL16, 360 (DIC), 34 CXCR2, 78 Dissociation constant (Kd), 87 CXCR2 inhibitor, 469 DNA damage response (DDR), 389 CXCR3-B, 246 DNA-dependent protein kinase (DNA-PK), CXCR4 inhibitors, 462 201 CX3CL1, 79 DNA polymerase β, 202 Cyclin D1, 223 DNase, 85 Cyclobutan pyrimidine dimers (CPDs), 202 DNase I, 118 Cyclooxygenase (COX), 12, 411 Docosahexaenoic acid (DHA), 458 Cyclophilin A, 467 Donor-specific transfusion (DST), 101 Cyclophilin D, 206, 276 Double-edged swords, 21, 469 Cyclophosphamide (Cy), 316, 469 Down syndrome critical region-1 (DSCR-1), Cyclosporin A, 276 407 CYP2F2, 392 Doxorubicin, 469 CysLT2R, 72 Drosophila melanogaster, 93–94 Cystathione-β-synthase (CBS), 238 Drug-induced senescence, 209 Cysteine protease, 97 Dscr1-lacZ mice, 408 Cysteinyl-leukotrienes (CysLT), 72 DSS-induced colitis, 391 Cystic fibrosis
Load more

Recommended publications
  • Cellular and Plasma Proteomic Determinants of COVID-19 and Non-COVID-19 Pulmonary Diseases Relative to Healthy Aging
    RESOURCE https://doi.org/10.1038/s43587-021-00067-x Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging Laura Arthur1,8, Ekaterina Esaulova 1,8, Denis A. Mogilenko 1, Petr Tsurinov1,2, Samantha Burdess1, Anwesha Laha1, Rachel Presti 3, Brian Goetz4, Mark A. Watson1, Charles W. Goss5, Christina A. Gurnett6, Philip A. Mudd 7, Courtney Beers4, Jane A. O’Halloran3 and Maxim N. Artyomov1 ✉ We examine the cellular and soluble determinants of coronavirus disease 2019 (COVID-19) relative to aging by performing mass cytometry in parallel with clinical blood testing and plasma proteomic profiling of ~4,700 proteins from 71 individuals with pul- monary disease and 148 healthy donors (25–80 years old). Distinct cell populations were associated with age (GZMK+CD8+ T cells and CD25low CD4+ T cells) and with COVID-19 (TBET−EOMES− CD4+ T cells, HLA-DR+CD38+ CD8+ T cells and CD27+CD38+ B cells). A unique population of TBET+EOMES+ CD4+ T cells was associated with individuals with COVID-19 who experienced moderate, rather than severe or lethal, disease. Disease severity correlated with blood creatinine and urea nitrogen levels. Proteomics revealed a major impact of age on the disease-associated plasma signatures and highlighted the divergent contri- bution of hepatocyte and muscle secretomes to COVID-19 plasma proteins. Aging plasma was enriched in matrisome proteins and heart/aorta smooth muscle cell-specific proteins. These findings reveal age-specific and disease-specific changes associ- ated with COVID-19, and potential soluble mediators of the physiological impact of COVID-19.
    [Show full text]
  • Influence of Serum Amyloid a (SAA1) And
    Influence of Serum Amyloid A (SAA1) and SAA2 Gene Polymorphisms on Renal Amyloidosis, and on SAA/ C-Reactive Protein Values in Patients with Familial Mediterranean Fever in the Turkish Population AYSIN BAKKALOGLU, ALI DUZOVA, SEZA OZEN, BANU BALCI, NESRIN BESBAS, REZAN TOPALOGLU, FATIH OZALTIN, and ENGIN YILMAZ ABSTRACT. Objective. To evaluate the effect of serum amyloid A (SAA) 1 and SAA2 gene polymorphisms on SAA levels and renal amyloidosis in Turkish patients with familial Mediterranean fever (FMF). Methods. SAA1 and SAA2 gene polymorphisms and SAA levels were determined in 74 patients with FMF (39 female, 35 male; median age 11.5 yrs, range 1.0–23.0). All patients were on colchicine therapy. SAA1 and SAA2 gene polymorphisms were analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). SAA and C-reactive protein (CRP) values were measured and SAA/CRP values were calculated. Results. The median SAA level was 75 ng/ml (range 10.2–1500). SAA1 gene polymorphisms were: α/α genotype in 23 patients (31.1%), α/ß genotype in 30 patients (40.5%), α/γ genotype in one patient (1.4 %), ß/ß genotype in 14 patients (18.9%), ß/γ genotype in 5 patients (6.8 %), and γ/γ geno- type in one patient (1.4%). Of the 23 patients who had α/α genotype for the SAA1 polymorphism, 7 patients had developed renal amyloidosis (30.4%) compared to only one patient without this geno- type (1/51; 2.0%); p < 0.001. SAA2 had no effect on renal amyloidosis. SAA1 and SAA2 genotypes had no significant effect on SAA levels.
    [Show full text]
  • BMC Medical Genomics Biomed Central
    BMC Medical Genomics BioMed Central Research article Open Access Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation Ming-Ling Chang*1, Chau-Ting Yeh1, Deng-Yn Lin1, Yu-Pin Ho1, Chen- Ming Hsu1 and D Montgomery Bissell2 Address: 1Liver Research Center and Department of Hepatogastroenterology, Chang Gung Memorial Hospital; Chang Gung University, College of Medicine, Taoyuan, Taiwan, Republic of China and 2Liver Center and Department of Medicine, University of California, San Francisco, San Francisco, CA, USA Email: Ming-Ling Chang* - [email protected]; Chau-Ting Yeh - [email protected]; Deng- Yn Lin - [email protected]; Yu-Pin Ho - [email protected]; Chen-Ming Hsu - [email protected]; D Montgomery Bissell - [email protected] * Corresponding author Published: 8 August 2009 Received: 11 July 2008 Accepted: 8 August 2009 BMC Medical Genomics 2009, 2:51 doi:10.1186/1755-8794-2-51 This article is available from: http://www.biomedcentral.com/1755-8794/2/51 © 2009 Chang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The pathogenesis of inflammation and fibrosis in chronic hepatitis C virus (HCV) infection remains unclear. Transgenic mice with constitutive HCV core over-expression display steatosis only. While the reasons for this are unclear, it may be important that core protein production in these models begins during gestation, in contrast to human hepatitis C virus infection, which occurs post-natally and typically in adults.
    [Show full text]
  • Gene Expression Signature for Biliary Atresia and a Role for Interleukin-8
    SUPPLEMENTARY “PATIENTS AND METHODS” “Gene expression signature for biliary atresia and a role for Interleukin-8 in pathogenesis of experimental disease” Bessho K, et al. PATIENTS AND METHODS Patients. Liver biopsies, serum samples and clinical data were obtained from infants with cholestasis enrolled into a prospective study (ClinicalTrials.gov Identifier: NCT00061828) of the NIDDK-funded Childhood Liver Disease Research and Education Network (www.childrennetwork.org) or from infants evaluated at Cincinnati Children’s Hospital Medical Center. For subjects with biliary atresia (BA), liver biopsies were obtained from 64 infants during the preoperative workup or at the time of intraoperative cholangiogram, with ages ranging from 22-169 days after birth (Supplementary Table 7). For subjects with intrahepatic cholestasis (serving as diseased controls, and referred to as non- BA), liver biopsy samples were obtained percutaneously or intraoperatively from 14 infants at the time of diagnostic evaluation, with ages ranging from 19-189 days. Their diagnosis were Alagille syndrome (N=1), multidrug resistance protein-3 deficiency (N=2), alpha-1-antitrypsin deficiency (N=2) and cholestasis with unknown etiology (N=9) (Supplementary Table 7). Representative liver biopsy photomicrographs are shown in Supplementary Figure 6A-D. A third group of normal controls (NC) consisted of liver biopsy samples obtained from 7 deceased-donor children aged 22-42 months as described previously (1). This group serves as a reference cohort, with the median levels of gene expression used to normalize gene expression across all patients in the BA and non-BA groups. This greatly facilitates the visual identification of key differences in gene expression levels between BA and non-BA groups.
    [Show full text]
  • Transdifferentiation of Human Mesenchymal Stem Cells
    Transdifferentiation of Human Mesenchymal Stem Cells Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Tatjana Schilling aus San Miguel de Tucuman, Argentinien Würzburg, 2007 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Martin J. Müller Gutachter: PD Dr. Norbert Schütze Gutachter: Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die von mir angegebenen Hilfsmittel und Quellen verwendet habe. Des Weiteren erkläre ich, dass diese Arbeit weder in gleicher noch in ähnlicher Form in einem Prüfungsverfahren vorgelegen hat und ich noch keinen Promotionsversuch unternommen habe. Gerbrunn, 4. Mai 2007 Tatjana Schilling Table of contents i Table of contents 1 Summary ........................................................................................................................ 1 1.1 Summary.................................................................................................................... 1 1.2 Zusammenfassung..................................................................................................... 2 2 Introduction.................................................................................................................... 4 2.1 Osteoporosis and the fatty degeneration of the bone marrow..................................... 4 2.2 Adipose and bone
    [Show full text]
  • Serum Amyloid a – a Review George H
    Sack Molecular Medicine (2018) 24:46 Molecular Medicine https://doi.org/10.1186/s10020-018-0047-0 REVIEW Open Access Serum amyloid A – a review George H. Sack Jr Abstract Serum amyloid A (SAA) proteins were isolated and named over 50 years ago. They are small (104 amino acids) and have a striking relationship to the acute phase response with serum levels rising as much as 1000-fold in 24 hours. SAA proteins are encoded in a family of closely-related genes and have been remarkably conserved throughout vertebrate evolution. Amino-terminal fragments of SAA can form highly organized, insoluble fibrils that accumulate in “secondary” amyloid disease. Despite their evolutionary preservation and dynamic synthesis pattern SAA proteins have lacked well-defined physiologic roles. However, considering an array of many, often unrelated, reports now permits a more coordinated perspective. Protein studies have elucidated basic SAA structure and fibril formation. Appreciating SAA’s lipophilicity helps relate it to lipid transport and metabolism as well as atherosclerosis. SAA’s function as a cytokine-like protein has become recognized in cell-cell communicationaswellasfeedbackininflammatory, immunologic, neoplastic and protective pathways. SAA likely has a critical role in control and possibly propagation of the primordial acute phase response. Appreciating the many cellular and molecular interactions for SAA suggests possibilities for improved understanding of pathophysiology as well as treatment and disease prevention. Keywords: Serum amyloid A, SAA, inflammation, amyloidosis, acute phase response (APR), arthritis, apolipoprotein, liver, cytokine, lipopolysaccharide (LPS), myeloid-derived suppressor cells (MDSC), atherosclerosis Background Both CRP and SAA are present, but at generally quite Homeostasis is essential for most biological systems.
    [Show full text]
  • A Link Between Inflammation and Metastasis
    Oncogene (2015) 34, 424–435 & 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc ORIGINAL ARTICLE A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4 MT Hansen1,8, B Forst1,8, N Cremers2,3, L Quagliata2, N Ambartsumian1,4, B Grum-Schwensen1, J Klingelho¨ fer1,4, A Abdul-Al1, P Herrmann5, M Osterland5, U Stein5, GH Nielsen6, PE Scherer7, E Lukanidin1, JP Sleeman2,3,9 and M Grigorian1,4,9 S100A4 is implicated in metastasis and chronic inflammation, but its function remains uncertain. Here we establish an S100A4- dependent link between inflammation and metastatic tumor progression. We found that the acute-phase response proteins serum amyloid A (SAA) 1 and SAA3 are transcriptional targets of S100A4 via Toll-like receptor 4 (TLR4)/nuclear factor-kB signaling. SAA proteins stimulated the transcription of RANTES (regulated upon activation normal T-cell expressed and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix metalloproteinase 2), MMP3, MMP9 and MMP13. We have also shown for the first time that SAA stimulate their own transcription as well as that of proinflammatory S100A8 and S100A9 proteins. Moreover, they strongly enhanced tumor cell adhesion to fibronectin, and stimulated migration and invasion of human and mouse tumor cells. Intravenously injected S100A4 protein induced expression of SAA proteins and cytokines in an organ-specific manner. In a breast cancer animal model, ectopic expression of SAA1 or SAA3 in tumor cells potently promoted widespread metastasis formation accompanied by a massive infiltration of immune cells.
    [Show full text]
  • Consensus Molecular Subtype Differences Linking Colon Adenocarcinoma and Obesity Revealed by a Cohort Transcriptomic Analysis
    medRxiv preprint doi: https://doi.org/10.1101/2021.08.31.21262900; this version posted September 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis Short Title: Obesity and colon cancer Michael W. Greene1*, Peter T. Abraham2, Peyton C. Kuhlers1,3, Elizabeth A. Lipke2, Martin J. Heslin4, Stanley T. Wijaya1 and Ifeoluwa Odeniyi1 1Department of Nutrition, Dietetics, and Hospitality Management, Auburn University, Auburn, AL 36849, USA 2Department of Chemical Engineering, Auburn University, Auburn, AL 36849, USA 3Department of Biostatistics, University of North Carolina at Chapel Hill, NC 27599, USA 4Mitchell Cancer Institute, The University of South Alabama, Mobile, AL 36604, USA *Corresponding author: Michael W. Greene [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.08.31.21262900; this version posted September 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract Background Colorectal cancer (CRC) is the third-leading cause of cancer-related deaths in the United States and worldwide.
    [Show full text]
  • High-Density Lipoproteins As Homeostatic Nanoparticles of Blood Plasma
    International Journal of Molecular Sciences Review High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma Vasily A. Kudinov 1,2,* , Olga Yu. Alekseeva 3,4 , Tatiana I. Torkhovskaya 5 , Konstantin K. Baskaev 2 , Rafael I. Artyushev 2 , Irina N. Saburina 1 and Sergey S. Markin 6 1 Laboratory of Cell Biology and Developmental Pathology, FSBSI Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; [email protected] 2 Experimental Drug Research and Production Department, Institute of Biomedical Chemistry, 119121 Moscow, Russia; [email protected] (K.K.B.); rifi[email protected] (R.I.A.) 3 Cell Physiology Laboratory, Institute of Biomedical Problems, Russian Academy of Sciences, 123007 Moscow, Russia; [email protected] 4 Department of Biochemistry, People’s Friendship University (RUDN University), 117198 Moscow, Russia 5 Laboratory of Phospholipid Transport Systems and Nanomedicines, Institute of Biomedical Chemistry, 119121 Moscow, Russia; [email protected] 6 Clinical Research Department, Institute of Biomedical Chemistry, 119121 Moscow, Russia; [email protected] * Correspondence: [email protected] Received: 15 October 2020; Accepted: 15 November 2020; Published: 19 November 2020 Abstract: It is well known that blood lipoproteins (LPs) are multimolecular complexes of lipids and proteins that play a crucial role in lipid transport. High-density lipoproteins (HDL) are a class of blood plasma LPs that mediate reverse cholesterol transport (RCT)—cholesterol transport from the peripheral tissues to the liver. Due to this ability to promote cholesterol uptake from cell membranes, HDL possess antiatherogenic properties. This function was first observed at the end of the 1970s to the beginning of the 1980s, resulting in high interest in this class of LPs.
    [Show full text]
  • Serum Amyloid a Proteins Induce Pathogenic TH17 Cells and Promote Inflammatory
    bioRxiv preprint doi: https://doi.org/10.1101/681346; this version posted June 25, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Serum Amyloid A Proteins Induce Pathogenic TH17 Cells and Promote Inflammatory Disease June-Yong Lee1,12, Jason A. Hall1,12, Lina Kroehling1, Lin Wu1, Tariq Najar1, Henry H. Nguyen1, Woan-Yu Lin1, Stephen T. Yeung2, Hernandez Moura Silva1, Dayi Li1, Ashley Hine2,3, P’ng Loke2, David Hudesman3,4, Jerome C. Martin5,6,7, Ephraim Kenigsberg5,8,9, Miriam Merad5,6,7, Kamal M. Khanna2,10 and Dan R. Littman1,11* 1. The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, NY 10016, USA 2. Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA 3. Inflammatory Bowel Disease Center, Division of Gastroenterology, New York University School of Medicine, New York, NY 10016 USA 4. Department of Medicine, Division of Gastroenterology, New York University School of Medicine, New York, NY 10016, USA 5. Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 6. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 7. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 8. Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 1 bioRxiv preprint doi: https://doi.org/10.1101/681346; this version posted June 25, 2019.
    [Show full text]
  • Chondrocytes from Osteoarthritis Patients Adopt Distinct Phenotypes in Response to Central TH1/TH2/TH17 Cytokines
    International Journal of Molecular Sciences Article Chondrocytes from Osteoarthritis Patients Adopt Distinct Phenotypes in Response to Central TH1/TH2/TH17 Cytokines Antti Pemmari 1 , Tiina Leppänen 1, Mari Hämäläinen 1, Teemu Moilanen 2 and Eeva Moilanen 1,* 1 The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, University of Tampere and Tampere University Hospital, 33100 Tampere, Finland; antti.pemmari@tuni.fi (A.P.); tiina.leppanen@tuni.fi (T.L.); mari.hamalainen@tuni.fi (M.H.) 2 Coxa Hospital for Joint Replacement, 33520 Tampere, Finland; teemu.moilanen@coxa.fi * Correspondence: eeva.moilanen@tuni.fi Abstract: Chronic low-grade inflammation plays a central role in the pathogenesis of osteoarthritis (OA), and several pro- and anti-inflammatory cytokines have been implicated to mediate and regulate this process. Out of these cytokines, particularly IFNγ, IL-1β, IL-4 and IL-17 are associated with different phenotypes of T helper (TH) cells and macrophages, both examples of cells known for great phenotypic and functional heterogeneity. Chondrocytes also display various phenotypic changes during the course of arthritis. We set out to study the hypothesis of whether chondrocytes might adopt polarized phenotypes analogous to TH cells and macrophages. We studied the effects of IFNγ, IL-1β, IL-4 and IL-17 on gene expression in OA chondrocytes with RNA-Seq. Chondrocytes were harvested from the cartilage of OA patients undergoing knee replacement surgery and then cultured with or without the cytokines for 24 h. Total RNA was isolated and sequenced, and GO (Gene Ontology) functional analysis was performed. We also separately investigated genes linked Citation: Pemmari, A.; Leppänen, T.; to OA in recent genome wide expression analysis (GWEA) studies.
    [Show full text]
  • Recombinant Mouse Serum Amyloid A1 Catalog Number: 2948-SA
    Recombinant Mouse Serum Amyloid A1 Catalog Number: 2948-SA DESCRIPTION Source E. coli-derived mouse Serum Amyloid A1 protein Gly20-Tyr122 Accession # P05366 N-terminal Sequence Gly20 Analysis Predicted Molecular 11.8 kDa Mass SPECIFICATIONS SDS-PAGE 11 kDa, reducing conditions Activity Measured by its ability to induce TNF-α secretion by J774A.1 mouse reticulum cell sarcoma macrophage cells. The ED50 for this effect is 1.5-7.5 μg/mL. Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. Formulation Lyophilized from a 0.2 μm filtered solution in Tris-HCl, NaCl, PEG and Imidazole. See Certificate of Analysis for details. PREPARATION AND STORAGE Reconstitution Reconstitute at 100 μg/mL in PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution. BACKGROUND Mouse Serum Amyloid A protein-1 (SAA1; previously SAA2 in mouse) is a multifunctional apolipoprotein produced by hepatocytes in response to pro-inflammatory cytokines (1 - 4). It is secreted as a 12 kDa, 103 amino acid (aa), nonglycosylated protein and circulates as part of the HDL complex (1 - 4). The SAA1 gene is one of five SAA genes in mouse (3).
    [Show full text]